Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Iterum Therapeutics PLC
NASDAQ ITRM
Data sourced from
and
and
Iterum Therapeutics PLC Revenue Per Share for the year ending December 31, 2023: USD 0.00
Iterum Therapeutics PLC Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.
-
Iterum Therapeutics PLC Revenue Per Share for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
-
Iterum Therapeutics PLC Revenue Per Share for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
-
Iterum Therapeutics PLC Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a -100.00% change year over year.
-
Iterum Therapeutics PLC Revenue Per Share for the year ending December 31, 2019 was USD 0.04, a -97.44% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ITRM
| CEO | Mr. Corey N. Fishman |
| IPO Date | May 25, 2018 |
| Location | Ireland |
| Headquarters | Fitzwilliam Court, Dublin, Ireland, 2 |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Key trends
Similar companies
Hoth Therapeutics Inc
USD 1.17
0.00%
StockViz Staff
September 8, 2024
Any question? Send us an email